Compare Consolidated Edison, Inc. (ED) vs Pfizer Inc (PFE) Price & Performance

Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $16.92B and net income of $2.02B for 2025, with a net margin of 11.95%. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. The stock is supported by a strong dividend history, with a recent $0.89 dividend declared for H2 2026, and positive news highlighting its economic impact in New York and involvement in electric bus infrastructure.

The outlook for ED is cautiously optimistic, with a consensus price target of $106.33 suggesting modest upside. Strengths include stable cash flow, a solid dividend, and strategic investments in infrastructure. Key risks involve fluctuating earnings, high debt levels, and regulatory pressures. Analyst sentiment is predominantly neutral, with 62.96% hold ratings, indicating a wait-and-see approach amid evolving utility sector dynamics.

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.